Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

the NDA; NeurogesX' plans, and expected timing, with regard to seeking partnerships for its product candidates; the sufficiency of cash resources to fund the NeurogesX' operations through at least December 31, 2009; the ability to secure funding through commercial partnerships; expectations regarding expenses and cash burn rate; expectations with respect to seeking funding; the potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, positive results in clinical trials, or the recommendation of the CHMP for MAA approval, may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; unexpected expenses; inability to enter into or obtain adequate funding under commercial or other strategic partnerships; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


                                     NEUROGESX, INC.
                             
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, ... MarCom Awards for outstanding creative achievement by its marketing ... Award, the organization’s top honor, in the Branding category ... in April of this year. The event showcased top ... Nerium was awarded a Gold MarCom Award in the ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... WARREN, N.J. , Nov. 25, 2014  Roka Bioscience, ... focused on providing advanced testing solutions for the detection of ... will present at the Piper Jaffray  26 th Annual ... conference will be held at The New York Palace in ... During this presentation, material information concerning the Company, its operations, ...
(Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
Breaking Biology Technology:Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today ... Life Sciences Conference in New York. A live ... 2007 at 2:00 p.m. Eastern,Time may be accessed ... will be archived for seven days. (Logo: ...
... September 24 ThalesNano Inc., a,leading developer ... and hydrogenation technology solutions, announced today that ... a subsidiary in the United,Kingdom and by ... Building its own subsidiary reflects ThalesNano,s ...
... (Nasdaq and MTAX: CTIC) today announced that Richard L. ... Chairman of the Board for,Systems Medicine, which was recently ... Genomics Institute ("TGen") in Arizona,uses the latest drug development ... and identify which drugs will be most effective,at treating ...
Cached Biology Technology:BioCryst to Present at UBS 2007 Global Life Sciences Conference 2BioCryst to Present at UBS 2007 Global Life Sciences Conference 3ThalesNano Inc. Opens Own Representation in the United Kingdom and has New Distribution Agreements for Europe and India 2Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) 2Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI) 3
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws against ... are piloting the North American and European automotive sector ... growing, gesture recognition systems that are intuitive and able ... in the industry. New analysis from ... Recognition Market in Europe and ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... detergent pods began appearing on U.S. store shelves in ... numbers ever since. The small packets can be tossed ... out a liquid or powder. The convenience, though, has ... study from researchers at Nationwide Children,s Hospital found that ... reports of 17,230 children younger than 6 years of ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... 2010 Scientists studying the environmental impact of Hurricane ... city of New Orleans have revealed the ecological impact ... The findings, published in a special issue of ... caused significant ecological damage by altering coastal chemistry and ...
... exposure to ionizing radiation can result in mutations or ... Now a new study led by researchers with the ... Lab) has revealed another way in which radiation can ... cells, the researchers discovered that radiation exposure can alter ...
... invasive aquatic organism that is on the state,s most ... Bay and Coos Bay, and scientists say this "colonial ... economic and environmental implications. Its propensity to foul ... buoys could make it costly to control, and its ...
Cached Biology News:New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3Study raises new concerns about radiation and breast cancer 2Study raises new concerns about radiation and breast cancer 3Invasive 'tunicate' appears in Oregon's coastal waters 2Invasive 'tunicate' appears in Oregon's coastal waters 3Invasive 'tunicate' appears in Oregon's coastal waters 4
... Ribonuclease Inhibitors have broad spectrum RNase inhibitory ... of the neutral type (1). The 50kDa ... binding to RNases in a 1:1 ratio. ... RNasin Ribonuclease Inhibitor to RNase (e.g., RNase ...
UGT1A7 (E-15)...
... corresponding to the third cytoplasmic loop of ... to KLH. The immunizing peptide has 79% ... Physical form: Solution in phosphate buffered ... Titertest method: IHC (p). Titertest ...
... Human Pathogenic Viruses The ... (NCPV) preserves well characterised, authenticated ... secure facility, and NCPV is ... or nucleic acids derived from ...
Biology Products: